Each tablet contains Amoxicillin 250 mg and Potassium Clavulanate IP (as Potassium Clavulanate Diluted IP) equivalent to Clavulanic Acid 125 mg.

Erox CV 375 Tablets combine the proven antibacterial activity of Amoxicillin with the β-lactamase inhibiting action of Clavulanic Acid. This combination broadens the antibacterial spectrum of Amoxicillin by protecting it from enzymatic degradation caused by β-lactamase-producing bacteria. Erox CV 375 is effective against a wide range of susceptible pathogens responsible for respiratory tract, ENT, skin, and urinary tract infections, making it a valuable therapeutic option in community-acquired bacterial infections.

Erox CV 375 Tablets are indicated for the treatment of lower respiratory tract infections, otitis media, sinusitis, skin and skin structure infections, and urinary tract infections caused by susceptible bacterial organisms.

Amoxicillin is a semisynthetic penicillin belonging to the β-lactam class of antibiotics. It exerts its bactericidal effect by inhibiting enzymes involved in bacterial cell wall peptidoglycan synthesis, resulting in cell wall destruction and bacterial death. Clavulanic Acid is a β-lactam compound structurally related to penicillins that inhibits certain β-lactamase enzymes produced by resistant bacteria. By preventing the enzymatic breakdown of Amoxicillin, Clavulanic Acid helps restore and extend its antibacterial activity against β-lactamase-producing pathogens.

The recommended dosage is one tablet administered orally every 8 hours or as directed by the physician. The duration of treatment should be based on the severity and type of infection and the patient’s clinical response.

Erox CV 375 Tablets are contraindicated in patients with known hypersensitivity to Amoxicillin, Clavulanic Acid, penicillins, cephalosporins, or any component of the formulation. The product should not be administered to patients who have experienced serious hypersensitivity reactions to β-lactam antibiotics, including penicillins and cephalosporins.